PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1584093
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1584093
GI Stool Testing Market size was valued at USD 550.20 Million in 2023, expanding at a CAGR of 7.80% from 2024 to 2032.
GI (Gastrointestinal) stool testing involves the analysis of a person's stool or feces to assess their digestive health, identify infections, and detect any underlying gastrointestinal (GI) issues. It is a non-invasive diagnostic tool used by healthcare professionals to evaluate a variety of conditions.
GI Stool Testing Market- Market Dynamics
Growing prevalence of infectious and gastrointestinal disorders and need for preventive diagnostics is expected to propel market demand
The global increasing prevalence of gastrointestinal disorders such as irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis, celiac disease, and colorectal cancer is driving demand for diagnostic tools like GI stool testing, thereby boosting market growth. These conditions often require stool analysis for proper diagnosis and monitoring. The growing prevalence of infectious gastrointestinal diseases caused by bacteria, viruses, and parasites fuels the need for stool testing. Travel, globalization, and the spread of antibiotic-resistant strains contribute to this demand. Increasing awareness of preventive healthcare measures and regular health screenings among individuals is driving the growth of GI stool tests. For instance, fecal occult blood tests (FOBT) are widely recommended for early detection of colorectal cancer, one of the most preventable cancers.
The availability of over the counter at-home GI stool testing kits has made it easier for individuals to monitor their digestive health from the comfort of their homes. Companies like Everlywell and Viome are popularizing this trend, making stool tests more accessible to a wider consumer base. Several healthcare organizations around the world are implementing screening programs for early detection of colorectal cancer. This drives the adoption of stool-based tests like FOBT and fecal immunochemical tests (FIT), especially in countries with high cancer incidence rates.
GI Stool Testing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.80% over the forecast period (2024-2032)
Based on Test Type segmentation, the bacteria tests segment was predicted to show maximum market share in the year 2023, owing to its high incidence of bacterial infections.
Based on Application segmentation, infectious diseases segment was the leading Application segment in 2023, due to the disorders cause by bacteria, and viral infections.
Based on End User segmentation, hospital & clinics segment was the leading End User segment in 2023, due to the growing need for treatment in disease like cancer, bowel disease, etc.
On the basis of region, North America was the leading revenue generator in 2023, due to the continuous tech advancement & awareness.
Global GI Stool Testing Market is segmented on the basis of Test Type, Application, End User, and Region.
The market is divided into four categories based on Test Type: bacteria tests, fecal biomarker tests, occult blood tests, and others. The bacteria tests segment dominates the market. Increasing tech innovations and advanced screening methods are promoting segment growth.
The market is divided into five categories based on Application: infectious diseases, inflammatory bowel disease, gastroesophageal reflux disease (GERD), cancer, and others. The infectious disease segment dominates the market. The increasing prevalence of viral infections and the need for stool-based tests is fueling market growth.
The market is divided into four categories based on End User: hospital & clinics, diagnostic centers, homecare, and others. The hospital & clinics segment dominates the market and is expected to maintain its high dominance during the forecast period. The need for early detection of GI diseases, cancer, advanced screening benefits are supplementing segment growth.
GI Stool Testing Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a sizable share of the global GI stool testing market due to advanced healthcare infrastructure, high prevalence of gastrointestinal disorders, and widespread awareness of preventive health measures. The U.S. has one of the highest rates of colorectal cancer, with routine screening programs in place for early detection. In Europe, Several European countries, including the U.K., Germany, and France, have national screening programs for colorectal cancer, driving demand for stool-based tests like FOBT and FIT. The Asia-Pacific region is expected to experience the fastest growth in the GI stool testing market. This is driven by an increasing incidence of gastrointestinal diseases, expanding healthcare infrastructure.
The competitive landscape of the GI Stool Testing market is moderately competitive in nature. Companies are focusing on advancing molecular diagnostics, including PCR, next-generation sequencing, and microarray technologies, to improve the sensitivity and specificity of GI stool tests. Increased research into the gut microbiome has led to new product development, with several companies offering tests that analyze gut bacteria for broader health insights. Market players are also developing rapid diagnostic tests that provide faster results, catering to point-of-care needs in hospitals and clinics.
In December 2022, Shineco, Inc. received US FDA approval and USPTO patent safeguarding for its innovative & advanced in-situ fecal specimen sampling device.
In 2022, Prenetics Group collaborated with New Horizon Health to launch new tool called ColoClear by Circle.